A Dual Marker for Monitoring MDR-TB Treatment: Host-Derived miRNAs and *M. tuberculosis*-Derived RNA Sequences in Serum

Claudia Carranza1, María Teresa Herrera2, Silvia Guzmán-Beltrán2, Manuel Guadalupe Salgado-Cantú2, Ivan Salido-Guadarrama2, Elizabeth Santiago3, Leslie Chávez-Galán4, Luis Horacio Gutiérrez-González5 and Yolanda González2*

1 Laboratorio de Inmunobiología de la Tuberculosis, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico, Mexico, 2 Department of Microbiology, National Institute for Respiratory Diseases Ismael Cosío Villegas, Mexico, Mexico, 3 Laboratorio de Biología Computacional, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico, Mexico, 4 Laboratory of Integrative Immunology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico, Mexico, 5 Department of Virology and Mycology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico, Mexico

Background: In the absence of a late marker of treatment failure or relapse in MDR-TB patients, biomarkers based on host-miRNAs coupled with *M. tuberculosis*-RNAs evaluated in extracellular vesicles (EVs) are an alternative follow-up for MDR-TB disease. Characterization of EVs cargo to identify differentially expressed miRNAs before and after treatment, and to identify *M. tuberculosis*-derived RNA in serum EVs from resistant TB patients.

Methods: EVs were isolated from serum of 26 drug-resistant TB (DR-TB) patients and 16 healthy subjects. Differential expression of miRNAs in pooled exosomes from both untreated and treated patients was assessed and individually validated at different time points during treatment. In addition, *M. tuberculosis* RNA was amplified in the same samples by qPCR.

Results: A multivariate analysis using miR-let-7e-5p, -197-3p and -223-3p were found to be a more sensitive discriminator between healthy individuals and those with TB for both DR-TB (AUC= 0.96, 95%, CI=0.907-1) and MDR-TB groups (AUC= 0.95, 95%, CI= 0.89-1). Upregulation of miR-let-7e-5p were observed at the time of *M. tuberculosis* negative culture T(3-5) for MDR-TB group or for long-term T(9-15) for MDR-TB group without T2DM. A second pathogen-based marker based on 30kDa and 5KST sequences was detected in 33% of the MDR-TB patients after the intensive phase of treatment. The miR-let7e-5p is a candidate biomarker for long-term monitoring of treatment for the group of MDR-TB without T2DM. A dual marker of host-derived miR-let7e-5p and *M. tuberculosis*-derived RNA for monitoring-TB treatment based in serum EVs.
INTRODUCTION

Tuberculosis (TB) is a transmissible disease which still is one of the top ten causes of death worldwide. Only in 2019, between 8.9 and 11 million lived with the active TB, and 2.4 million people died from it. One quarter of the world population could already be infected with Mycobacterium tuberculosis (M. tuberculosis) and, therefore, at risk of developing the active form of the disease (1).

The risk of TB reactivation increases significantly in people with risk factors such as diabetes mellitus (DM), human immunodeficiency virus (HIV) co-infection, and many other conditions associated with immunocompromise (1).

Currently, treatment of drug-sensitive TB consists of a six-month regimen based on four drugs. However, drug-resistant TB (DR-TB) is defined when a person has drug resistant TB for at least one of the main TB drugs, and multi drug resistant TB (MDR-TB) is defined when a person has drug resistance to rifampicin and isoniazid, the two most efficacious first-line anti-tuberculosis drugs. Both types of drug resistant TB remain as significant challenges and major contributors to mortality. According to the same report from WHO, TB-DR killed 465,000 people in 2019 (1). Drug resistance is more probable in patients non-compliance to treatment or a primary infection with a drug-resistant strain (DR-TB) (2, 3). Treatment for multidrug resistant tuberculosis (MDR-TB) treatment is longer (two years), more toxic and much less successful (57% cure rate) (1).

Most diagnostic tests for TB are based on either bacteriological culture or polymerase-chain reactions (PCR). Traditionally, sputum smear microscopy has been the most widely used test. Despite its high specificity, its diagnostic value is limited by its very low sensitivity. Cultures, on the other hand, can take up to 42 days to reveal detectable growth (4, 5). The Xpert MTB/RIF and the ultra-version tests detect genetic material from M. tuberculosis, with a sensitivity similar to microbial cultures (6). These tests yield quick results but are costly and not widely available (7).

All these diagnostic assays require a positive culture for M. tuberculosis. However, sputum samples from individuals with active TB, especially those with type 2 diabetes mellitus (T2DM), often fail to yield bacteria. In these cases, invasive procedures are often needed for diagnosis (8). Thus, sensitive, and specific diagnostic tests that can spare patients from more invasive procedures are warranted.

A negative sputum culture is generally considered a marker of treatment success. Nevertheless, some patients develop recurrent TB despite negative sputum cultures, which may indicate the presence of viable but nonculturable bacteria. Therefore, a reliable marker of recovery or recurrence is clearly needed (9).

Conclusion: A dual marker consisting of host-derived miR-let7e-5p and M. tuberculosis-derived RNA, could be an indicator of treatment failure or relapse time after treatment was completed.

Keywords: drug resistance to TB, miRNAs, exosomes, M. tuberculosis-RNA, monitoring treatment
METHODS

Study Participants
Twenty-six patients with DR-TB were studied between 2010 and 2018. DR-TB group included those with rifampicin resistant (RR), multi-drug resistant (MDR), and extensively drug-resistant (XDR) strains; all patients had a confirmed diagnosis of TB and were under Directly Observed Therapy (DOT). Patients were followed for 15 months at the Instituto Nacional de Enfermedades Respiratorias (INER) in Mexico City. A blood sample was taken at each follow-up visit. This sample was centrifuged to obtain serum and stored at -80°C. Additionally, 16 healthy volunteers were included as control group and their samples underwent the same procedure. An informed consent was obtained from all participants. The use of these samples was approved by the Institutional Review Board. Written consent was obtained from all participants, and the Ethics Committee approved this study (No. C57-17).

Biological Samples Tested
We analyzed the samples from 26 TB patients with drug resistant TB diagnoses (21 MDR, three RR and two XDR); the blood samples were taken at: T(0), untreated patients; T(3-5), one sample between 3 to 5 months after treatment; T(6-8), one sample between 6 to 8 months after treatment, and T(9-15), one sample between 9 to 15 months after treatment. A total of four samples per patient were processed. The samples were classified into four categories: 1) those from DR-TB patients exhibiting any resistance types (RR, MDR or XDR); 2) those from MDR-TB patients with T2DM (MDR-TB-T2DM+); 3) those from MDR-TB patients without T2DM (MDR-TB-T2DM−); and 4) those from MDR-TB patients with T2DM (MDR-TB-T2DM+).

Exosomes Extraction From Serum
Exosomes were purified from the serum using the Exo-Quick™ exosome precipitation solution (System Biosciences, USA), following the instructions of the manufacturer, and adding a filtration procedure step with a 0.22 μm filter before the procedure. In brief, filter serum was centrifuged at 3000 g and ExoQuick™ exosome precipitation solution was added and incubated, then it was centrifuged at 1500 g and the pellet was resuspended in 200 μl of PBS. Exosomes or EVs were obtained from 300 μl of serum to perform DNA and RNA extraction, protein extraction and miRNA analysis. EVs were stored at -20°C until further processing.

Extraction and Quantification of Exosomes Proteins
Protein was obtained from 100 μl of exosomes using buffer RIPA (cat. 89901, Fisher Scientific, USA) plus a protease inhibitor cocktail (cat. 78430, Thermo Fisher Scientific, USA). The mix was sonicated for 15 seconds for total lysis and then centrifuged at 14000 g for 15 minutes at 4°C. The supernatant was recovered, and total protein was quantified using the Quick Start assay (cat. 500-0202, Bio-Rad, USA). The absorbance was read at 595 nm (Epoch™, Biotek) and the protein quantitation was calculated by standard curve.

Extraction of Total Small RNAs and miRNA Retrotranscription From Serum Exosomes
The RNA was obtained with the MagMAX™ miRana™ Total RNA Isolation Kit (cat. A27828, Applied Biosystems-Thermo Fisher Scientific, USA), which was used as per the instructions of the manufacturer. The total RNA of exosomes was recovered and stored at -20°C until further use. For RNA synthesis of complementary DNA was used the TaqMan™ Advanced miRNA cDNA Synthesis Kit (cat. A28007, Applied Biosystems-Thermo Fisher Scientific, USA) following the manufacturer instructions. RNA-samples were thawed and underwent three procedures in sequence: first a polyadenylation of miRNA catalyzed by one poliA polymerase, then an adaptive ligation and finally a retrotranscription by an inverse transcriptase. The complementary DNA (cDNA) was synthetized in the Step One Plus instrument (Applied Biosystems, Thermo Fisher Scientific, USA), according to manufacturer instructions and stored at -20°C until further use.

Evaluation of Endogenous miRNAs Expression From Exploratory Array
The miRNA Human Endogenous Controls 96-well Plate TaqMan™ Advanced (cat. A34462, Applied Biosystems-Thermo Fisher Scientific, USA) was used to evaluate 30 endogenous control miRNAs, including two exogenous (non-human) controls for normalization of sample input. Briefly, PCR was performed mix the TaqMan Fast Advanced Master Mix (cat. A44360 Applied Biosystems-Thermo Fisher Scientific, USA) and the pool of cDNA from five MDR-TB patients before treatment (T0) or after 12 months of treatment (T12) and the mix was added to plates. The qPCR was run in the Step One Plus instrument according to manufacturer instructions. The data are shown in the Supplementary File.
Evaluation of Exosome miRNAs Expression From Exploratory Array and Individual Validation

We used pre-spotted TaqMan Advanced miRNA assays in a 96-well fast plate (cat. A31813 Applied Biosystems, Thermo Scientific, USA). This kit contains two plates for 188 unique miRNAs for serum/plasma samples, 2 exogenous controls (cel-miR-39-3p, ath-miR159a) and an endogenous control (hsa-miR-16-5p) for normalization of data results. Briefly, PCR was performed by mixing the TaqMan Fast Advanced Master Mix solution and the pool of cDNA from five MDR-TB patients at T(0) or T(12), and added to plates. The qPCR was run in the Step One Plus instrument, according to manufacturer instructions. The differentially expressed miRNAs in the pool at T(0) vs T(12) are shown in the workflow (Figure 1) and in the Supplementary File.

For individual validation, we selected eight miRNAs: two endogenously expressed at CT<25, three miRNAs expressed at T(0) and down-expressing after 12 months with CT<32, and three miRNAs not expressed at T(0) and up-expressed at T(12) with CT<32. Briefly, cDNA for individual miRNAs expression was evaluated at four different times: T(0), T(3-5), T(5-8) and T(9-15), when it was mixed with the TaqMan Fast Advanced Master Mix and the specific probe for microRNA assays (Custom TaqMan® Applied Biosystems, ThermoFisher Scientific, CA, USA), according to the below table.

| miRNA name   | Target sequence                  |
|--------------|----------------------------------|
| hsa-miR-20a-3p| ACUGCAUUAUGAAGGCUUAAAG           |
| hsa-miR-195-5p| UAGGACGACAGAAAUAUGGC             |
| hsa-miR-328-3p| CUGGCUCUCUCUCCUCUCGU             |
| hsa-miR-145-5p| GUCCAGUUUUCAGGAAUCCCU            |
| hsa-let-7e-5p | UAGAGGUGAGGUGUGUGUAGUU           |
| hsa-miR-197-3p| UUGACCAACCUUCUCACACG             |
| hsa-miR-223-3p| UGUCAGUUGUGUAAUACCCCA            |
| hsa-miR-451a  | AAACGUGUACCAUAUUGAGU             |

The qPCR was run in the Step One Plus instrument, according to manufacturer instructions. The CT values of individual miRNAs are shown in the Supplementary File.

DNA and Total RNA Exosome Extraction and M. tuberculosis Sequences Amplification by qPCR

The DNA was isolated with the Exosomal DNA Extraction Kit (101Bio, USA) according to the manufacturer instructions. RNA was extracted with the total exosome RNA and protein isolation kit (Invitrogen-ThermoFisher Scientific, USA) according to the manufacturer instructions. Then, the complementary DNA (cDNA) was synthetized using RNA as template and the TaqMan™ MicroRNA Reverse Transcription kit (cat. 4366597, Applied Biosystem-Thermo Fisher Scientific, USA) with hexamers (cat. N8080127, Invitrogen, Thermo Fisher Scientific Inc., USA), and was amplified using a thermocycler Verity (Applied Biosystems-ThermoFisher Scientific, USA).

Finally, mycobacterial sequences were evaluated by quantitative real time PCR (qPCR), using exosomal cDNA, Maxima SYBR™ Green/ROX qPCR Master Mix (Thermo Scientific Inc., USA), and the specific forward/reverse primers for M. tuberculosis antigens.

The DNA from M. tuberculosis H37Rv strain was included as positive control and water for PCR was used as a negative control. In the samples, a result was considered positive when the melting temperature was comparable to the positive control. Then, we visualized the amplicons in agarose gel electrophoresis (1.8%) with GelRed (cat. 41003, Bioutum) and documented by the ChemiDocMP Imaging System.

Statistical Analysis

Raw CT data were normalized using the Delta CT method (2-ΔΔCT). To that end, average expression stability (defined as M-value) of the reference miRNA was determined using the GeNorm algorithm (20). Briefly, this method iteratively compares the mean expression value of tested miRNAs and selects those with lowest M-value. Then, for each sample we subtracted the CT value of the most stable miRNA from the CT value of the remaining miRNAs.

Expression differences between cases and controls were assessed by an unpaired two-samples Mann-Whitney test. To evaluate changes in expression that are associated to treatment, expression at different endpoints (i.e., T(3-5), T(6-9) and T(9-15) months) were compared against expression at T(0). Significance was evaluated with a Wilcoxon signed-rank test and a p-value < 0.05 was considered significant. Receiver Operating Characteristics (ROC) analysis and multiple regression were performed with the pROC package and the glm function in R, respectively. The evaluation of transitions was based on the 6ΔCT value between all the possible time points for all samples of study. The analysis was done using the Matlab R2017b software.

RESULTS

Characteristics of Study Groups

The patients with drug resistant TB included patients with rifampicin resistant (RR), multi-drug resistant (MDR), and...
extensively drug-resistant (XDR) strains; all patients had a confirmed diagnosis of TB and were under Directly Observed Therapy (DOT). The 14% of patients were underweight. The main comorbidity was type 2 diabetes mellitus (T2DM), 33% of patients have it. Sixteen age- and sex-matched healthy subjects were included for miRNAs expression analysis (Table 1).

Forty miRNAs Differentially Expressed Before and at 12-Month Follow-Up Treatment Were Identified in the Pool of Exosomal miRNAs

There are no constitutive genes for the evaluation of miRNAs; therefore, endogenous genes are used to perform normalization of miRNA expression. The analysis of 32 endogenous miRNAs in a pool of serum exosomes from five MDR-TB patients comparing T(0) vs T(12) did not show any stable endogenous miRNAs at any of these time points (Supplementary File). However, the analysis of the expression of an array of 180 miRNAs in the same pool of miRNAs showed 10 stable miRNAs in the serum exosome pool at T(0) and (T12), and we selected two of them to normalize the data. Additionally, we identified 40 miRNAs up- or down-expressed at T(0) vs T(12). Six were up-expressed at T(0) and 34 were up-expressed at T(12) (Figure 1).

Of the 40 miRNAs, we analyzed eight individually: miR-223-3p and -451a, -20a-3p, -195-5p and -328-5p, -145-5p, -197-3p and -let7e-5p. We identified miR145-5p as the miRNA that is more consistently expressed during TB treatment. Therefore, we used it to calculate the ΔCT. The miRNAs expression from individual serum exosomes are shown in the Supplementary File.

Differential Expression of miR-197-3p, miR-223-3p and miR-let7e-5p in DR-TB Disease

The molecular testing shows 69% sensitivity for smear-negative, culture-positive specimens (21). Since some patients with suspected TB cannot be diagnosed through these methods, here we analyzed miRNA expression associated to DR-TB diagnosis.
We identified three miRNAs associated to DR-TB disease: miR-197-3p and -223-3p, which are downregulated, and miR-let7e-5p, which is upregulated in DR-TB patients compared to healthy subjects (Figure 2A). Since the most represented group was that of MDR-TB, we focused our search for differential miRNA expressions in this group, only to find that the same statistical differences were conserved (Figure 2B).

**miRNA-Model Increases the Sensitivity and Specificity for TB Disease**

We calculated the sensitivity and specificity of miR-197-3p, -223-3p and -let7e-5p performing a ROC curve analysis, both as single predictors and in combination using a multivariable model to distinguish the DR-TB or MDR-TBs group from the group of samples from healthy individuals. We observed that miRNA-Model reached an Area Under the Curve value (AUC) = 0.96 (95% CI=0.907-1) for DR-TB patients (Figure 3A and Table 2) and AUC= 0.95, (95% CI= 0.89-1) for MDR-TB patients (Figure 3B and Table 2), showing to be a more sensitive discriminator between healthy and diseased individuals.

**miRlet-7e-5p and miR328-3p Expression Change at the Time of M. tuberculosis Negative Culture in DR or MDR TB Patients**

A sputum culture-negative conversion is currently the most objective indicator of response during early stage of TB treatment (22). Thus, miRNA expression at T(3-5) months was analyzed after all patients showed negative sputum cultures. At this time point, significant changes in miR-328-3p and -let-7e-5p levels were detected: miR-328-3p was upregulated, whereas miR-let-7e-5p was downregulated (Figure 4A). Since some expression levels for some patients did not change the same way, an additional analysis was performed in the subgroup of samples from MDR-TB patients, where a significant difference for miR-20a-3p, -328-3p and -let-7e-5p was observed (Figure 4B).

---

**TABLE 1 | Characteristics of the study participants.**

|                        | Patients (n=26) | Healthy controls (n=15) | P value |
|------------------------|----------------|------------------------|---------|
| Age, yr                | 43.5 (19–77)   | 45 (27–61)             | 0.6859  |
| Sex, male (%)          | 18 (69.2)      | 10 (66.6)              | >0.9999 |
| BMI                    | 23.2 (17–27)   | 26 (23-33)             | 0.0050  |
| Comorbidities          |                |                        |         |
| Diabetes (%)           | 9 (34.5)       | –                      | –       |
| Alcoholism (%)         | 9 (34.5)       | –                      | –       |
| Smoking (%)            | 2 (7.7)        | –                      | –       |
| Malnutrition (%)       | 15 (5.7)       | –                      | –       |
| Pulmonary Tuberculosis |                |                        |         |
| RR/MDR-TB (%)          | 3 (15.4)       | –                      | –       |
| MDR-TB (%)             | 21 (73)        | –                      | –       |
| XDR-TB (%)             | 2 (7.7)        | –                      | –       |
| TB Treatment           |                |                        |         |
| Individualized (%)     | 9 (42.8)       | –                      | –       |
| Clinical data          |                |                        |         |
| Leukocytes/WBC count, x10³/mm³ | 9.7 (4.3–18.8) | –                      | –       |
| Neutrophil count, x10³/mm³ | 7.4 (1.7–17.3) | –                      | –       |
| Lymphocyte count, x10³/mm³ | 1.6 (0.9–2.4)  | –                      | –       |
| Hematocrit %           | 41.2 (27.2–52.8) | –                   | –       |
| Hemoglobin g/ml        | 13.6 (9.4–17.7) | –                      | –       |
| NLR ratio              | 4.8 (0.9–18.8) | –                      | –       |
| Metabolic characteristics |                |                        |         |
| HbA1c % T2DM           | 9.2 (5.5–13.5) | –                      | –       |
| Glucose, mg/dl         | 99 (75-525)    | –                      | –       |
| Blood Chemistry Profile|                |                        |         |
| Creatinine, mg/dl      | 0.76 (0.51-1.1) | –                      | –       |
| BUN, mg/dl             | 10 (5.8–20)    | –                      | –       |
| Albumin, mg/dl         | 3.6 (2.3–4.4)  | –                      | –       |
| Urea, mg/dl            | 22 (12.4–42)   | –                      | –       |
| Renal function         |                |                        |         |
| MDRD ml/min/1.73 m²    | 109.3 (67–1767.3) | –                | –       |
| CKD/EPI ml/min         | 104 (64–134)   | –                      | –       |
| CrCL ml/min            | 102.3 (49–209.2) | –                 | –       |
| Nephrotoxicity         | 17.4%          | –                      | –       |
| Hearing damage         | 36%            | –                      | –       |

*Individualized include the drugs: standard antibiotics and others such as amoxicillin, clavulanic acid, ceftriaxone, linezolid, clofazimine and dalamanid. BMI, Body Mass Index; RR/MDR-TB, Rifampicin-Resistant-MDR TB; MDR-TB, Multi-drug-resistant TB; XDR-TB, Extensively drug-resistant TB; WBC, White Blood Cell; NLR, Neutrophil-Lymphocyte Ratio; HbA1c, hemoglobin A1c; BUN, Blood Urea Nitrogen; MDRD, Modification of Diet in Renal Disease; CKD/EPI, Chronic Kidney Disease Epidemiology Collaboration; CrCL, Creatinine clearance rate.
Long-Term Treatment Monitoring Was Associated With miR-let-7e-5p in the Group of MDR-TB Without T2DM

Treatment monitoring should be performed at least once a month during the intensive treatment phase (first six months), and then every 1 or 2 months during the continuation phase. Delay to identify treatment failure or the emergence of resistant strains of pulmonary TB leads to severe disease and transmission (22). No differences in the expression of miR-20a-3p, -195-5p, -197-3p, -223-3p, -328-3p, -451a and -let-7e-5p at T(6-8) or T(9-...
15) were found between the DR and MDR groups. Given that T2DM is a metabolic disorder that can affect biomarker assessment, we performed an additional analysis excluding patients with T2DM. As shown in Figure 4C, miR-let7e-5p was differentially expressed at early time points T(3-5), as well as at the late time points T(6-8) and T(9-15).

**Transition Probabilities of miR-let-7e-5p Over Time Points as an Indicator of Changes**

Since long-term identification of miRNAs could be an indicator of drug failure or relapse, an additional analysis was conducted to evaluate the transition pattern of miRNAs between timepoints. The diagram of comparisons or transitions between the timepoints (stages) is shown in Figure 5A. It was found that miR let-7e-5p is the only miRNA that reported an increase in ΔCT values in most comparisons, maintaining a probability greater than 50%. The transitions of miR-let7e-5p to an upregulated or downregulated state over time are shown in a heatmap (Figure 5B). The probabilities for the miR let-7e-5p associated to the MDR-TB and MDR-TB-T2DM(-) groups are shown in Figure 5C. We found concordance between the changes observed in Figure 5 with the transition probability analyses at the more distant T(6-8) and T(9-12) time points (Figure 5).

**Presence of 30kDa and 5KST RNA From *M. tuberculosis* in Serum Exosomes of DR or MDR TB Patients**

Although biomarkers based on the host response to *M. tuberculosis* are useful diagnostic tools, they may be affected by new or concomitant diseases. We found that the long-term expression of miR-let-7e-5p was associated only with MDR-TB patients without DM, and that some patients did not change in the same way. Therefore, it was necessary to search for a second pathogen-based marker.

---

**TABLE 2 | ROC analysis for DR-TB or MDR-TB groups vs Healthy subjects.**

| Group         | miR        | AUC   | AUCCI.min | AUCCI.max | Cutpoint (-ΔCt) | Sensitivity | Specificity |
|---------------|------------|-------|-----------|-----------|----------------|-------------|-------------|
| DR-TB         | miR-197-3p | 0.909 | 0.803     | 1         | -0.054         | 0.652       | 0.933       |
|               | let-7e-5p  | 0.728 | 0.555     | 0.9       | 0.985          | 0.87        | 0.933       |
|               | 223-3p     | 0.863 | 0.744     | 0.981     | -1.523         | 0.8         | 0.812       |
|               | model-miR(197-3p + let-7e-5p +223-3p) | 0.96 | 0.907     | 1         | 0.714          | 0.8         | 1           |
| MDR-TB        | 197-3p     | 0.895 | 0.775     | 0.92      | -0.054         | 0.65        | 0.933       |
|               | let-7e-5p  | 0.74  | 0.56      | 0.92      | 0.985          | 0.85        | 0.933       |
|               | 223-3p     | 0.848 | 0.714     | 0.977     | -1.523         | 0.765       | 0.812       |
|               | model-miR(197-3p + let-7e-5p +223-3p) | 0.953 | 0.89      | 1         | 0.714          | 0.765       | 1           |

AUC, Area Under the Curve.

---

**FIGURE 4** | miRNAs detection at the time of *M. tuberculosis* negative culture from DR-TB patients and treatment monitoring from MDR-TB without T2DM. miRNAs expression analyzed at T(0) and T(3-5). The data are expressed as ΔCt, box plots depict medians and quartiles. Lines show the expression change for each patient. **(A)** DR-TB patients, **(B)** MDR-TB patients, and **(C)** MDR-TB without T2DM. Wilcoxon signed-rank test T(0) vs. T(3-5) or T(6-8) or T(9-15). Only statistical differences with p < 0.05 are shown.
The presence of pathogen-derived RNA in exosomes released during macrophage infection has been reported (23). In view of the heterogeneity of the exosome cargo, we decided to evaluate the presence of proteins, DNA, and RNA sequences from TB patients. Neither DNA sequences (Mpb64, 5KST, 19kDa, CFP-10, ESAT-6, Mpt64, 30kDa and Ag85c) nor proteins (ESAT-6, CFP-10, 38kDa, Ag85b and MPT64) were found in serum exosomes from DR-TB patients (data not shown). Nevertheless, RNA sequences for 30kDa and 5KST antigens in the serum exosomes from DR-TB patients were found. Figure 6 shows the time point of *M. tuberculosis* antigen expression and PCR products in a heat map (Figure 6B). Antigens were expressed before treatment in 50% of DR-TB patients. However, after the intensive phase of treatment, *M. tuberculosis* RNA sequences were detected in only 33%. These data could also suggest treatment failure or relapse.

**A Dual Marker for Monitoring MDR-TB Treatment**

Finally, miR-let-7e-5p expression and *M. tuberculosis* antigens detected in the exosomes of MDR-TB at T(9-15) were evaluated for concordance. Figure 7A shows the change in miR-let7e-5p expression over time from T(9-15) in MDR-TB patients; despite the significant differences, the expression of miR-let7e-5p did not increase in some patients. Thus, the data have been disaggregated into two subgroups: one for exosomes negative to *M. tuberculosis* (Figure 7B), in which an increase of miR-let7e-5p is observed in all patients, and one for exosomes positive to 30kDa or 5KST proteins, in which miR-let7e-5p expression decreased in 60% of the patients (Figure 7C).

**DISCUSSION**

Despite recent advances in TB research, diagnosis and treatment monitoring still remain a global challenge, further exacerbated by the emergence of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains (24). It has been reported that *M. tuberculosis* may use exosomes as a mechanism for releasing molecules into host cells. The molecules identified are proteins, peptides and small RNA sequences (miRNAs) derived from both
The expression of these three miRNAs is associated with an increased likelihood of MDR-TB in a multivariate model (ROC curve AUC= 0.96 and CI of 0.907-1). To our knowledge, this specific pattern of miRNAs expression had not been previously reported. It had been observed that miR-let-7e-5p, -let-7d-5p, -450a-5p, and -140-5p were expressed among patients with LTBI (28), while miR-223-3p was decreased in plasma samples from patients with TB compared to healthy controls (29). Now we are adding to those findings the observation that the expression of miR-let-7e-3p is downregulated while miR-223-3p is increased in MDR-TB patients. According to our data and those published by Lingna et al., miR-let-7e-5p is suppressed during the active phase of the TB caused for any strain of *M. tuberculosis*, while its expression is increased in the TB-latent or after one year of drug treatment for MDR-TB patients, suggesting its use as a possible biomarker for non-resistant and resistant pulmonary TB (18).

miRNAs have regulatory functions: miR-223-3p targets the gene STAT1, involved in interferon-gamma signaling during TB disease (29); miR-let-7e-5p acts as a tumor suppressor, and its down-regulation may promote the development and progression of carcinomas (30). Finally, miR-197-3p binds to the interleukin-1beta (IL-1β) receptor, contributing to autoinflammatory processes (31). Nevertheless, the role of these miRNAs in tuberculosis remains to be determined.

To date, only microbiological methods based on sputum sample are available to monitor TB treatment; however, an important limitation of these methods lies in the availability of biological samples, since patients stop expectorating a few months after starting treatment. Furthermore, even if bacilli are detected again in sputum, few changes in the therapeutic regimen can be made (22). For this reason, we propose measuring miRNAs as part of the monitoring of DR-TB treatment: if at the time of sputum conversion T(3-5), the miR-let-7e-5p expression becomes downregulated, while the miR-328-3p is up-expressed, it is likely that RR, MDR or XDR strains have appeared. Additionally, we have shown that the up-expression of a particular miRNA, the miR-20a-3p, is associated with a specific type of resistance: that of the MDR group. Thus, miR-328-3p and -let-7e-5p expression could be useful to analyze in conjunction with other clinical and microbiological data to monitor DR-TB patients during the early stages of treatment.

To summarize, to evaluate early-term treatment efficacy, we propose to determine two miRNAs (miR-let-7e-5p and -328-3p) for all DR-TB patients and three miRNAs (miR-let-7e-5p, -328-3p and -20a-3p) for MDR-TB patients. The strategy of using a set of biomarkers had been suggested previously for MDR-TB diagnosis: specifically, with a model based on five biomarkers (CD44, KNG1, and miR-4433b-5p, -424-5p, and -199b-5p) (32). However, the latter study has important differences with our own, namely, the type of sample (serum) and the tools used (liquid chromatography-tandem mass spectrometry and sequencing).

The main challenge of this study was to find a biomarker to predict treatment failure or relapse after the completion of the intensive phase (22). Although we expected to find biomarkers that could be useful for all patients regardless of their comorbidities, we did not find any miRNA expression pattern applicable to the MDR-TB group in general, but only in MDR-TB patients without T2DM.
In this group, we observed that miR-328-3p and -let7e-5p correlate with the time of smear conversion T(3-5), and that miR-let7e-5p correlates with the intensive phase of treatment T(9-15). Based on these data, miR-let7e-5p expression may be a biomarker in patients with MDR-TB without T2DM.

The presence of T2DM in TB patients not only tends to make biomarker assessment more difficult. On one hand, oral antihyperglycemic drugs can alter the pharmacokinetics, safety, and clinical effects of anti-TB drugs. On the other, T2DM patients are also at a higher risk of TB treatment failure, death, and relapse after cure. Therefore, treatment for TB-T2DM patients needs to be personalized to lower resistance rates and to have better outcomes (33, 34).

Additionally, the probabilities of transitions, comparing all the times studied, led to identify the miR-let-7e-5p in both the MDR-TB and MDR-TB-T2DM(-) groups, with higher transition probability at the more distant T(6-8) and T(9-12) time points, thus supporting its use as a potential biomarker.

Despite the advantages of biomarkers as non-invasive diagnostic tools, circulatory miRNAs have been reported to be redundant to similar miRNAs in various diseases and to be influenced by external factors such as smoking, diet, circadian cycles, etc. This makes difficult to link circulatory miRNAs to specific diseases (35).

For these reasons, we evaluated a second M. tuberculosis-derived marker of the presence of proteins, DNA and RNA sequences in the serum exosomes from MDR-TB patients. Thus, sequences were amplified for 30kDa and 5KST antigens of M. tuberculosis from exosomal-RNA at T(9-15) after the intensive phase of treatment. A concordance between the expression of miR-let-7e-5p and the M. tuberculosis antigens was observed in the exosomes of 60% of patients after the intensive phase of treatment. When the expression of miR-let7e-5p decreases, the RNA for either 30kDa or 5KST proteins are detected.

A limitation of this study lies on the heterogeneity of the patients, the reduced number of DR-TB patients, and the failure to detect a miRNA associated with T2DM. Nevertheless, the results may be useful in the non-diabetic population.

CONCLUSION

A dual marker presents in serum exosomes, consisting of host-derived miR-let7e-5p and M. tuberculosis-derived RNA for 30kDa or 5KST, may detect treatment failure or relapse for MDR-TB patients. We propose this double evaluation as a method of a long-term monitoring of TB treatment. Given the lack of methods
available for detection of drug failure or relapse, these tests could help clinicians to make adjustments to therapeutic regimens and improve the control of TB in their patients.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The Ethics Committee from the Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas approved this study (No. C57-17). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

CC, MTH, MS-C, and YG made sample assays and data analysis. IS-G, ES, and SG-B analyzed and interpreted the data. LC-G analyzed the results. LHG-G and YG designed the study and wrote the manuscript. All authors contributed to the article and approved the submitted version.

REFERENCES

1. WHO. (2020). Geneva Switzerland. Available at: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2020.
2. Furin J, Cox H, Pai M. Tuberculosis. Lancet (2019) 393:1642–56. doi: 10.1016/S0140-6736(19)30308-3
3. Shah NS, Auld SC, Brust JCM, Mathema B, Ismail N, Moodley P, et al. Transmission of Extensively Drug-Resistant Tuberculosis in South Africa. N Engl J Med (2017) 376:243–53. doi: 10.1056/nejmoa1604544
4. Lagrange PH, Thangaraj SK, Dayal R, Despande A, Ganguly NK, Girardi E, et al. A Toolbox for Tuberculosis Diagnosis: An Indian Multicentric Study (2006-2008): Microbiological Results. PLoS One (2012) 7:1–14. doi: 10.1371/journal.pone.0043739
5. Davies PDO, Pai M. The Diagnosis and Misdiagnosis of Tuberculosis. Int J Tuberc Lung Dis (2008) 12(11):1226–34.
6. Geotti D, Lee M-R, Wang J-Y, Walter N, Ottenhoff THM. Update on Tuberculosis Biomarkers: From Correlates of Risk, to Correlates of Active Disease and of Cure From Disease. Respirology (2018) 23:455–66. doi: 10.1111/resp.13272
7. Zellweger JP, Sotgia G, Block M, Dore S, Allet N, Blanschi R, et al. Risk Assessment of Tuberculosis in Contacts by IFN-γ Release Assays. A Tuberculosis Network European Trials Group Study. Am J Respir Crit Care Med (2015) 191:1176–84. doi: 10.1164/rccm.201502-0332OC
8. Lönroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of TB Epidemics: The Role of Risk Factors and Social Determinants. Soc Sci Med (2009) 68:2240–6. doi: 10.1016/j.socscimed.2009.03.041
9. Ottenhoff THM, Ellner JJ, Kaufmann SHE. Ten Challenges for TB Biomarkers. Tuberculosis (2012) 92:517–20. doi: 10.1016/S1472-9792(12)70007-0
10. Alipoor SD, Mortaz E, Garssen J, Movassaghi M, Mirsaedi M, Adcock IM. Exosomes and Exosomal miRNA in Respiratory Diseases. Mediators Inflamm (2016) 2016:1–11. doi: 10.1155/2016/5628404
11. Alipoor SD, Mortaz E, Tabarsi P, Farnia P, Mirsaedi M, Garssen J, et al. Bovis Bacillus Calmette-Guérin (BCG) Infection Induces Exosomal miRNA Release by Human Macrophages. J Transl Med (2017) 15:1–9. doi: 10.1186/s12977-017-1205-9

DATA AVAILABILITY STATEMENT

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.760468/full#supplementary-material

SUPPLEMENTARY MATERIAL

FUNDING

Fondo Sectorial de Investigacion en Salud y Seguridad Social (FOSISS), Proyecto No. 00000000290282, Consejo Nacional de Ciencia y Tecnología (CONACyT), Mexico.

ACKNOWLEDGMENTS

We thank Marcela Muñoz, Norma A Tellez-Navarrete, Daniel Juárez Carmona and Laura Elena Carreto Binaghi for clinical data, and Enrique Camacho Mezquita for style review.
China: A Cross-Sectional Study in Three Geographic Varied Provinces. PloS One (2016) 11:1–13. doi: 10.1371/journal.pone.0146340

25. Kuipers ME, Hokke CH, Smits HH, Nolte-’t Hoen ENM. Pathogen-Derived Extracellular Vesicle-Associated Molecules That Affect the Host Immune System: An Overview. Front Microbiol (2018) 9:2182. doi: 10.3389/fmicb.2018.02182

26. Kruh-Garcia NA, Wolfe LM, Chaissom LH, Worodria WO, Nahid P, Shovey JS, et al. Detection of Mycobacterium Tuberculosis Peptides in the Exosomes of Patients With Active and Latent M. Tuberculosis Infection Using MRM-MS. PloS One (2014) 9:1–11. doi: 10.1371/journal.pone.0103811

27. Standards D. American Thoracic Society. Diagnostic Standards and Classification of Tuberculosis. Am Rev Respir Dis (1990) 142:725–35. doi: 10.1164/ajrccm/142.3.725

28. Yong YK, Tan HY, Saeidi A, Wong WF, Vignesh R, Velu V, et al. Immune Biomarkers for Diagnosis and Treatment Monitoring of Tuberculosis: Current Developments and Future Prospects. Front Microbiol (2019) 10. doi: 10.3389/fmicb.2019.02789

29. Yi X-H, Zhang B, Fu Y-R, Yi Z-J. STAT1 and its Related Molecules as Potential Biomarkers in Mycobacterium Tuberculosis Infection. J Cell Mol Med (2020) 24:1–13. doi: 10.1111/jcmm.14856

30. Wang S, Jin S, Liu M-D, Pang P, Wu H, Qi ZZ, et al. Hsa-Let-7e-5p Inhibits the Proliferation and Metastasis of Head and Neck Squamous Cell Carcinoma Cells by Targeting Chemokine Receptor 7. J Can cer (2019) 10:1941–8. doi: 10.7150/jca.29536

31. Akkaya-Ulum YZ, Akbaba TH, Tavukcuoglu Z, Chae JJ, Yilmaz E, Ozen S, et al. Familial Mediterranean Fever-Related miR-197-3p Targets LLR1 Gene and Modulates Inflammation in Monocytes and Synovial Fibroblasts. Sci Rep (2021) 11:1–10. doi: 10.1038/s41598-020-80097-4

32. Wang C, Liu CM, Wei LL, Shi LY, Pan ZF, Mao LG, et al. A Group of Novel Serum Diagnostic Biomarkers for Multidrug-Resistant Tuberculosis by iTRAQ-2D LC-MS/MS and Solexa Sequencing. Int J Biol Sci (2016) 12:246–56. doi: 10.7150/ijbs.13805

33. Luftiana NC, van Boven JM, Masoom Zubair MA, Pena MJ, Alffenaar JW. Diabetes Mellitus Comorbidity in Patients Enrolled in Tuberculosis Drug Efficacy Trials Around the World: A Systematic Review. Br J Clin Pharmacol (2019) 85:1407–17. doi: 10.1111/bcp.13935

34. Wu B, Miller D. Involvement of microRNAs in Diabetes and its Complications. Methods Mol Biol (2017) 1617:225–39. doi: 10.1007/978-1-4939-7046-9_17

35. Nagaraj S. Pros and Cons of miRNAs as Non-Invasive Circulatory Biomarkers. Res Rev Res J Biol (2017) 5:1–7.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Carranza, Herrera, Guzmán-Beltrán, Salgado-Cantú, Sádlo-Guadarrama, Santiago, Chávez-Galán, Gutiérrez-González, and González. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.